Drugs

Lab testing supports workplace and safety programs, clinical care (pain management, behavioral health, addiction treatment), and legal/compliance needs. Results help document use or adherence, but they do not prove impairment, intent, or exact dosing. Always interpret findings with a qualified professional and follow the applicable policy.

Signs, Situations & Related Needs

• Workplace/safety: pre-employment, random, return-to-duty, post-incident testing

• Clinical care: pain-management adherence, medication-assisted treatment (MAT), unexpected behaviors, potential interactions

• Legal/compliance: court-ordered monitoring, custody/probation requirements, program abstinence checks

• Risk indicators: early refills, lost prescriptions, inconsistent histories, prior substance use

• Urgent care: suspected overdose, severe sedation, chest pain, suicidal ideation—seek immediate medical help
  All testing should be interpreted by a clinician, Medical Review Officer (MRO), or program administrator.

Why These Tests Matter

What drug testing can do

• Detect presence/absence of target drug classes and confirm specific compounds with metabolites

• Differentiate adherence vs. non-adherence and identify undisclosed substances

• Provide objective trends to guide visit frequency, counseling, or program steps

What drug testing cannot do

• Prove impairment, exact dose, or time since use

• Replace clinical judgment, chain-of-custody procedures, or program policies

• Explain motive or context without additional information

What These Tests Measure (at a glance)

• Opioids & semisynthetics: morphine, codeine, 6-MAM (heroin), hydrocodone/hydromorphone, oxycodone/oxymorphone, fentanyl/norfentanyl, methadone/EDDP, buprenorphine/norbuprenorphine

  • Use: adherence in pain/MAT; undisclosed opioid exposure; metabolite patterns verify biotransformation

• Stimulants: amphetamine/methamphetamine (option for D/L isomer), MDMA/MDA, methylphenidate metabolites

  • Use: rule out cross-reactivity; confirm specific stimulant

• Cocaine: benzoylecgonine, ecgonine methyl ester

  • Use: definitive cocaine exposure

• Cannabinoids: THC-COOH (urine), parent THC (blood/oral fluid)

  • Use: matrix-dependent window (recent vs. residual)

• Benzodiazepines: alprazolam/α-hydroxyalprazolam, lorazepam, oxazepam, temazepam, clonazepam/7-aminoclonazepam

  • Use: detect glucuronidated benzos missed by some screens

• Barbiturates, PCP, synthetic opioids/novel psychoactives: targeted as ordered

• Specimen validity (urine): creatinine, specific gravity, pH, oxidants

  • Use: detect dilution, substitution, or adulteration

Typical detection windows (vary by dose, frequency, matrix, and cutoff)

• Urine: ~1–3 days for many drugs; longer for THC with frequent use

• Oral fluid: hours to ~1–2 days (recent use)

• Blood: hours to ~1 day (current presence)

• Hair: weeks–months (long-term pattern; not impairment)

How the Testing Process Works

1. Define your goal & matrix: recent use, long-term pattern, or adherence; choose urine, oral fluid, blood, or hair.

2. Screen, then confirm: run an immunoassay screen; perform LC-MS/MS or GC-MS confirmation for non-negative or policy-directed classes.

3. Collection & custody: follow instructions; some settings require observed collection and chain-of-custodydocumentation.

4. Results & review: secure report lists analytes, metabolites, and levels (plus validity metrics for urine).

5. Trend over time: schedule repeat testing to document change, adherence, or relapse prevention.

Interpreting Results (General Guidance)

• Confirmed positive: target analyte(s) at/above cutoff—review metabolite profile (e.g., oxycodone with oxymorphone, fentanyl with norfentanyl) and prescriptions.

• Negative/below cutoff: not detected or under threshold—does not exclude use outside the detection window.

• Special markers: 6-MAM (heroin), norfentanyl (fentanyl), EDDP (methadone), norbuprenorphine(buprenorphine) reinforce interpretation.

• Matrix matters: oral fluid/blood = recent; urine = clearance; hair = long-term pattern.
  Always interpret alongside medication lists, timing, clinical findings, and program rules.

Choosing Panels vs. Individual Tests

• Workplace/safety programs: standard multi-drug panels with confirmation as required; include specimen validity for urine.

• Pain management/MAT: targeted opioid ± benzodiazepine panels with metabolite confirmation.

• Unexpected screen results: broaden to definitive LC-MS/MS confirmation; consider isomer testing for amphetamines.

• Long-term pattern monitoring: hair panels; pair with periodic urine/oral fluid for near-term checks.

• Suspected tampering: add specimen validity to urine testing.

FAQs

What’s the difference between a screen and a confirmation test?
A screen is a rapid yes/no immunoassay; confirmation uses mass spectrometry to precisely identify and quantify drugs/metabolites.

Does a positive test prove impairment?
No. It shows presence above a cutoff, not impairment or exact timing.

Which specimen is best?
Match the window to the goal: blood (now), oral fluid (recent), urine (recent/clearance), hair (weeks–months).

Can prescriptions cause a positive screen?
Yes. That’s why confirmation is used to separate cross-reactivity from true positives.

How do metabolite patterns help?
They verify biologic processing (e.g., 6-MAM for heroin) and help distinguish adherence from non-prescribed use.

What if I suspect dilution or adulteration?
Order specimen validity (creatinine, specific gravity, pH, oxidants) and follow collection policy.

Internal Links & Cross-References

• Drug & Alcohol Tests Hub

• Drug Screening

• Drug Confirmation Test

• Drug Monitoring

• Drug Toxicology Monitoring

• Alcohol

• Key Lab Tests: Multi-Drug Screen (Urine/Oral Fluid) • LC-MS/MS Drug Confirmation • Hair Drug Panel • Opioid/Benzodiazepine Targeted Confirmation • Fentanyl/Norfentanyl Confirmation • Specimen Validity

References

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug testing guidance and cutoffs.

2. U.S. Department of Transportation (DOT). Drug Testing Program regulations.

3. American Society of Addiction Medicine (ASAM). Appropriate use of drug testing in clinical addiction medicine.

4. American Association for Clinical Chemistry (AACC). Definitive drug testing best practices.

5. College of American Pathologists (CAP). Toxicology and chain-of-custody standards.

6. ARUP Consult/clinical toxicology compendia. Detection windows, metabolite interpretation, and specimen validity.

Available Tests & Panels

Your drugs testing menu is pre-populated in the Ulta Lab Tests system. Select the matrix and panel that match your goal, pair screening with LC/GC-MS confirmation when required, and include specimen validity for urine. Review all results with your clinician, MRO, or program administrator.